Healthcare Industry News: Ceplene
News Release - December 12, 2006
EpiCept Announces Relocation of Corporate Headquarters to Tarrytown, New York
TARRYTOWN, N.Y., Dec. 12 (HSMN NewsFeed) -- EpiCept Corporation (Nasdaq: EPCT; OMX Stockholm) today announced that it has relocated its corporate headquarters from Englewood Cliffs, New Jersey to Tarrytown, New York, effective immediately in order to accommodate future planned growth for the Company.EpiCept's R&D activities will remain in its San Diego facility and the Company will continue to possess an in-house clinical research unit in Munich, Germany, for the management of the European clinical development of drug candidates.
The Company's main offices are now located at 777 Old Saw Mill River Road, Tarrytown, New York, 10591. The telephone number for the Company has been changed to (914) 606-3500. Additional contact details can be found by visiting www.epicept.com.
About EpiCept Corporation
EpiCept is an emerging specialty pharmaceutical company focused on unmet needs in the treatment of pain and cancer. The Company has a staged portfolio of product candidates with several pain therapies in late-stage clinical trials, and a lead oncology compound (for acute myeloid leukemia, AML) with demonstrated efficacy in a Phase III trial; a marketing authorization application for this compound has been submitted in Europe. EpiCept is based in New York, and the Company's research and development team in San Diego is pursuing a drug discovery program focused on novel approaches to apoptosis.
Forward-Looking Statements
This news release and any oral statements made with respect to the information contained in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements which express plans, anticipation, intent, contingency, goals, targets, future development and are otherwise not statements of historical fact. These statements are based on the Company's current expectations and are subject to risks and uncertainties that could cause actual results or developments to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Factors that may cause actual results or developments to differ materially include: the risk that Ceplene will not receive regulatory approval or marketing authorization in the EU, the risk that our other product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later stage clinical trials, the risk that the Company will not obtain approval to market any of its product candidates, the risks associated with reliance on additional outside financing to meet its capital requirements, the risks associated with reliance on collaborative partners and others for further clinical trials, development, manufacturing and commercialization of our product candidates; the cost, delays and uncertainties associated with our scientific research, product development, clinical trials and regulatory approval process; our history of operating losses since our inception; competition; litigation; the potential delisting of our common stock by the Nasdaq Global Market; risks associated with the material weaknesses in our internal controls and the outcome of our SOX 404 audit; and risks associated with our ability to protect our intellectual property. These factors and other material risks are more fully discussed in the Company's periodic reports, including its reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange Commission. You are urged to carefully review and consider the disclosures found in the Company's filings, which are available at www.sec.gov or at www.epicept.com. You are cautioned not to place undue reliance on our forward-looking statements, any of which could turn out to be wrong due to inaccurate assumptions, unknown risks or uncertainties or other risk factors.
Source: EpiCept
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
